Hikma Pharmaceuticals (LON:HIK) Stock Passes Above Two Hundred Day Moving Average - Should You Sell?

Key Points

• Hikma Pharmaceuticals shares moved above their 200-day moving average, reaching GBX 1,667 and last trading at GBX 1,659.74 on heavy volume.
• Analysts remain bullish: six firms rate the stock “Buy,” with a consensus price target of GBX 2,060. Recent target increases range from GBX 1,870 to GBX 2,100.
• An insider purchased 7,500 shares at GBX 1,648, while company insiders own 22.04% of the stock.

Shares of Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 1,458.40 and traded as high as GBX 1,667. Hikma Pharmaceuticals shares last traded at GBX 1,659.74, with a volume of 44,098,535 shares trading hands.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on HIK. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and issued a GBX 1,950 price target on shares of Hikma Pharmaceuticals in a research report on Friday, August 7th. Citigroup upped their target price on shares of Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the company a "buy" rating in a research note on Wednesday, August 12th. Berenberg Bank increased their target price on shares of Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a "buy" rating in a report on Tuesday, August 11th. Finally, Jefferies Financial Group lifted their price target on shares of Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the stock a "buy" rating in a research report on Tuesday, May 5th. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Hikma Pharmaceuticals has an average rating of "Buy" and a consensus price target of GBX 2,060.

Hikma Pharmaceuticals Stock Performance

The company has a market cap of £3.47 billion, a price-to-earnings ratio of 9.17, a price-to-earnings-growth ratio of 2.38 and a beta of 0.66. The company has a debt-to-equity ratio of 77.57, a current ratio of 1.98 and a quick ratio of 1.27. The stock has a 50-day moving average price of GBX 1,565.50 and a 200 day moving average price of GBX 1,458.40.

Insider Buying and Selling

In related news, insider Tobias Hestler purchased 7,500 shares of the business's stock in a transaction on Monday, August 10th. The shares were purchased at an average price of GBX 1,648 per share, with a total value of £123,600. Company insiders own 22.04% of the company's stock.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source